Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Usti Nad Labem – page 30

1 086 clinical trials in Usti Nad Labem, Czechia across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Usti Nad Labem at a glance
1 086
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 086 trials in Usti Nad Labem

Open in trial search

Chondrosarcoma

Recruiting

Study of ivosidenib in adults with advanced or metastatic chondrosarcoma with IDH1 mutation who are untreated or have had one prior treatment

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Stopping Esomeprazole in Patients with Liver Cirrhosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Study of Lenvatinib, Pembrolizumab, and Chemotherapy Combination for Patients with Advanced Esophageal Cancer Previously Treated with PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Study of RMC-6236 and Pembrolizumab with or without Chemotherapy for Patients with RAS-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Study on Treating Resistant Viral Infections in Stem Cell Transplant Patients Using Allogeneic Multivirus-Specific T Cells

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Allogeneic Cd4+ And Cd8+ T Lymphocytes Ex Vivo Incubated With Synthetic Peptides Of The Viral Antigens Of Cytomegalovirus, Adenovirus And Epstein-Barr Virus
  • Sponsor:Medical Center - University Of Freiburg

Study of TL-895 for Patients with Relapsed or Refractory Myelofibrosis or Indolent Systemic Mastocytosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Flixebrutinib
  • Sponsor:Telios Pharma Inc.

Herpes simplex+1

Recruiting

Study on the Effect of Acyclovir in ICU Patients with Pneumonia and Herpes Simplex Virus Type 1 Detected in Lung Fluid

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obrixtamig
  • Sponsor:Boehringer Ingelheim International GmbH

Other cities in Czechia

The busiest research cities in the country

All 150 cities in Czechia

Clinical research in Usti Nad Labem

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials focusing on cardiovascular disease management and prevention, including studies on hypertrophic cardiomyopathy and treatments for acute myocardial infarction.

  • Heart failure treatments
  • Stroke prevention
  • Deep vein thrombosis therapy

Several studies are evaluating novel compounds to reduce cardiovascular events and improve patient outcomes.

02 Gastrointestinal Studies

Multiple clinical investigations targeting Crohn's Disease, with research focusing on innovative therapies and treatment combinations for moderate to severe cases.

  • Inflammatory bowel disease management
  • Novel therapeutic approaches
  • Long-term disease control

Research aims to improve quality of life for patients with chronic gastrointestinal conditions.

03 Metabolic Disorders

Comprehensive research into diabetes management and hypertriglyceridemia, including specialized treatments for both Type 1 and Type 2 diabetes in various age groups.

  • Blood sugar control
  • Lipid management
  • Pediatric diabetes care

Studies focus on developing targeted therapies for better metabolic control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.